NCT03267329View on ClinicalTrials.gov

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

September 2, 2020

Study Completion Date

September 2, 2020

Conditions
HypertensionDyslipidemia
Interventions
DRUG

Duowell®

telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%

DRUG

Telmisartan

telmisartan 80mg

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT03267329 - Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension | Biotech Hunter | Biotech Hunter